1. Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models.
- Author
-
Corthay, Alexandre, Lundin, Katrin U., Munthe, Ludvig A., Frøyland, Marianne, Gedde-Dahl, Tobias, Dembic, Zlatko, and Bogen, Bjarne
- Subjects
- *
MULTIPLE myeloma , *TUMORS , *T cells , *MONOCLONAL antibodies , *CANCER cells , *IMMUNOSPECIFICITY - Abstract
Multiple myeloma (MM) cells produce monoclonal immunoglobulin (Ig) which serves as a truly tumor-specific antigen. The tumor-specific antigenic determinants are localized in the variable (V)-regions of the monoclonal Ig and are called idiotopes (Id). We review here the evidence obtained in a T-cell receptor (TCR) transgenic mouse model that Id-specific, MHC class II–restricted CD4+ T cells play a pivotal role in immunosurveillance and eradication of MHC class II-negative MM cells. In brief, monoclonal Ig secreted by MM cells is endocytosed and processed by antigen-presenting cells (APCs) in the tumor. Such tumor-resident dendritic cell APCs in turn present Id peptide on their class II molecules to Id-specific CD4+ T cells which become activated and indirectly kill the MHC class II-negative myeloma cells. However, if the Id-specific CD4+ cells fail to eliminate the MM cells during their initial encounter, the increasing number of tumor cells secretes so much monoclonal Ig that T-cell tolerance to Id is induced. Extending these findings to MM patients, Id-specific immunotherapy should be applied at a time of minimal residual disease and when new Id-specific T cells have been educated in the thymus, like after high-dose chemotherapy and autologous stem cell transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF